EMAIL THIS PAGE TO A FRIEND

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Physiological relevant in vitro evaluation of polymer coats for gastroretentive floating tablets.


PMID 25086221

Abstract

Gastroretentive drug delivery systems are retained in the stomach for a sufficient time interval, releasing the drug in a controlled manner. According to literature, the floating principle is the most frequently used formulation approach for gastric retention. However, many publications lack information of the floating forces, the impact of different pH-values and almost no information exist concerning the resistance of the floating performance against physiological relevant stress. Therefore, we evaluated the performance of CO2-generating floating bilayer (drug and floating layer) tablets with respect to robustness, drug release profile, pH dependence and floating behaviour. Bilayer tablets were coated with a flexible and water permeable, but CO2-retaining polymer film of either polyvinyl acetate or ammonio-methacrylate copolymer type A. Metformin-HCl was used as a relevant model drug due to its dose-dependent and saturable absorption from the proximal part of the small intestine. To mimic physiological relevant mechanical stress conditions, recently developed dissolution stress tests with pulsed pressures were applied in addition to release studies according to the pharmacopeia. Bilayer tablets coated with polyvinyl acetate showed short floating lag times, reasonable floating strength values, floating durations of more than 24h in simulated gastric fluid and a robust and pH independent release of Metformin-HCl. Tablets coated with ammonio-methacrylate copolymer type A showed a higher permeability for the active ingredient combined with a decreased robustness of the inflated tablets. Both polymers can be used for balloon-like floating devices. The appropriate polymer has to be chosen dependent from the properties of the active ingredient and requested application of the delivery device. Furthermore, the dissolution stress test analysis is able to indicate possible safety issues of gastroretentive formulations as well as to characterise the robustness of formulation principles towards mechanical stresses of bio-relevant intensity.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

1009923
Acetyltriethyl citrate, United States Pharmacopeia (USP) Reference Standard
C14H22O8
26454
Magnesium stearate, puriss., meets analytical specification of Ph. Eur., BP, ≥90% stearic and palmitic acid basis, ≥40% stearic acid basis (GC), 4.0-5.0% Mg basis (calc on dry sub.)
C36H70MgO4
415057
Magnesium stearate, technical grade
C36H70MgO4
677469
Titanium(IV) oxide, contains 1% Mn as dopant, nanopowder, <100 nm particle size (BET), ≥97%
O2Ti
718467
Titanium(IV) oxide, nanopowder, 21 nm primary particle size (TEM), ≥99.5% trace metals basis
O2Ti
774510
Titanium(IV) oxide, nanowires, diam. × L ~100 nm × 10 μm
O2Ti
774529
Titanium(IV) oxide, nanowires, diam. × L ~10 nm × 10 μm
O2Ti
637254
Titanium(IV) oxide, anatase, nanopowder, <25 nm particle size, 99.7% trace metals basis
O2Ti
232033
Titanium(IV) oxide, anatase, powder, 99.8% trace metals basis
O2Ti
248576
Titanium(IV) oxide, anatase, powder, −325 mesh, ≥99% trace metals basis
O2Ti
634662
Titanium(IV) oxide, mixture of rutile and anatase, nanopowder, <100 nm particle size (BET), 99.5% trace metals basis
O2Ti
700355
Titanium(IV) oxide, mixture of rutile and anatase, nanoparticle, <250 nm particle size (DLS), paste, 53-57 wt. % in diethylene glycol monobutyl ether/ethylene glycol, 99.9% trace metals basis
O2Ti
700347
Titanium(IV) oxide, mixture of rutile and anatase, nanoparticles, <150 nm particle size (volume distribution, DLS), dispersion, 40 wt. % in H2O, 99.5% trace metals basis
O2Ti
700339
Titanium(IV) oxide, mixture of rutile and anatase, nanoparticles, <100 nm particle size, dispersion, 48-52 wt. % in xylene, 99.9% trace metals basis
O2Ti
204730
Titanium(IV) oxide, rutile, 99.995% trace metals basis
O2Ti
204757
Titanium(IV) oxide, rutile, ≥99.98% trace metals basis
O2Ti
635057
Titanium(IV) oxide, rutile, <001>, (single crystal substrate), ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm
O2Ti
635049
Titanium(IV) oxide, rutile, <100>, (single crystal substrate), ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm
O2Ti
635065
Titanium(IV) oxide, rutile, <110>, single crystal substrate, ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm
O2Ti
637262
Titanium(IV) oxide, rutile, nanopowder, <100 nm particle size, 99.5% trace metals basis
O2Ti
224227
Titanium(IV) oxide, rutile, powder, <5 μm, ≥99.9% trace metals basis
O2Ti
W200700
Triacetin, 99%, FCC, FG
C9H14O6
PHR1410
Triacetin, Pharmaceutical Secondary Standard; Certified Reference Material
C9H14O6
525073
Triacetin, 99%
C9H14O6
74103
Triacetin, analytical standard
C9H14O6
1675007
Triacetin, United States Pharmacopeia (USP) Reference Standard
C9H14O6